A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover,
single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100
mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under
fasting conditions.